⌘K
Loading ticker…
As of 2026-08-25, Kailera Therapeutics, Inc. Common Stock (KLRA) has a 3-month relative strength percentile of 22 within the TickerStance CS+ADRC universe (~5,000 tickers). The current market Stance is 52.9 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 6.3%, relative volume 2.49×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Not enough history to compute monthly seasonality for KLRA.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
KLRA is held by 4 ETFs as of May 2026. Top owner: VTWO at 0.00% weight, $725K notional. Top 3 carry $819K.
Held by 4 ETFs · $833K across latest filings · largest weight 0.00% (VTWG).
Top 4 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTWO | 0.00% | $725K | new |
| VTWG | 0.00% | $71K | new |
| VTWV | 0.00% | $23K | new |
| VTHRVanguard Russell 3000 ETF | 0.00% | $14K | new |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News